This article is more than 5 years old. Information may no longer be current.
Trials begun to evaluate empagliflozin for treatment of HF
Two trials have been initiated to study empagliflozin for the treatment of adults with HF with or without type 2 diabetes, according to a press release from Boehringer Ingelheim and Eli Lilly.
The outcome studies, part of the EMPEROR HF trial program, will investigate empagliflozin (Jardiance, Boehringer Ingelheim) in adults with HF with preserved ejection fraction or reduced ejection fraction.
"[HF] is a global health burden. We need to explore new treatment options, especially for those types of [HF] where treatments are currently limited," Milton Packer, MD, professor of medicine at Baylor Heart and Vascular Institute and Baylor University Medical Center, said in the release. "The EMPA-REG OUTCOME trial demonstrated a significant reduction in the risk [for CV] death with empagliflozin in adults with type 2 diabetes and [CVD]. And now these new EMPEROR HF clinical trials will take a dedicated look at the effects of empagliflozin in [patients with HF]."
In a secondary endpoint of EMPA-REG OUTCOME, empagliflozin was associated with a 35% reduced risk for HF hospitalization, according to the release.
Primary endpoints for the EMPEROR HF trials are CV death and hospitalization for HF.
Target enrollment is 7,000 participants and target completion date is 2020.